Cowen & Co. Keeps Their Buy Rating on ImmunoGen (IMGN)

By Ryan Adsit

Cowen & Co. analyst Boris Peaker maintained a Buy rating on ImmunoGen (IMGNResearch Report) today. The company’s shares closed last Monday at $3.80.

According to, Peaker is a 3-star analyst with an average return of 1.2% and a 42.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Pacira Pharmaceuticals, and Emergent Biosolutions.

Currently, the analyst consensus on ImmunoGen is a Moderate Buy with an average price target of $5.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.13 and a one-year low of $1.76. Currently, ImmunoGen has an average volume of 1.79M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.